Novartis Says Tislelizumab Met Primary Endpoint Of OS In Pivotal Phase III Trial – Quick Facts

(RTTNews) – Novartis AG (NVS) announced Friday results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy.

The study evaluated tislelizumab in patients with unresectable recurrent locally advanced or metastatic…